Novo Deal Turns HIMS Into a Tactical Long—Here’s a Playbook

Hook & thesis

Hims & Hers (HIMS) has just demonstrated that partnerships can be more than nice headlines—they can be switch flips. The March deal with Novo Nordisk removed a major legal overhang, reopened the company’s GLP-1 distribution channel and sent the shares sharply higher. That reversal offers a tactical long: the market has likely underpriced the re-acceleration opportunity while over-discounting legal risk.

My thesis is simple: with the Novo feud resolved and GLP-1 access restored, HIMS should see revenue re-acceleration into its sizeable telehealth base. The stock is actionable now because the structural growth runway (telehealth, dermatology, sexual health and GLP-1 additions) still exists, short interest is high enough to fuel momentum, and the company’s public targets remain ambitious ($2.8B for 2026). This is a mid-term swing trade sized for volatility, not a passive buy-and-hold.

What Hims & Hers does and why the market should care

HIMS operates a telehealth consultation and e-commerce platform connecting consumers to clinicians and treatments across mental health, dermatology, sexual health and primary care. The company’s ability to add high-margin, high-demand products (notably GLP-1 weight-loss drugs such as Wegovy and Ozempic) directly to its platform is a major differentiator: it turns routine telehealth visits into recurring prescription and product revenue.

The Novo Nordisk deal announced in early March resolved a lawsuit and reinstated access to two marquee GLP-1 products. That matters because GLP-1s drove outsized growth in recent periods and are a revenue multiplier per patient. Management still targets $2.8 billion in sales for 2026, and the company reported a record quarter earlier this year: $619 million in revenue in Q4 (reported around 02/23/2026), with EPS that beat expectations.

Hard numbers that support the case

Those numbers give both upside and caution. A $6.07 billion market cap at ~$26.62 implies the market values future GLP-1 contributions conservatively relative to the company’s own target and recent growth cadence. Q4’s $619 million shows scale; management’s $2.8 billion 2026 goal implies materially higher run-rate if GLP-1s meaningfully re-accelerate adoption on the platform.

Technical and positioning notes

The stock has been volatile: it traded as low as $13.74 in late February and as high as $70.43 in mid-2025. Short interest has been substantial (85M+ shares at the last report), and recent days posted heavy short volume—conditions that can amplify rallies once a key overhang (the Novo lawsuit) is removed. Momentum indicators are bullish: the 10-day SMA is near $18.27 while the price is well above it, and MACD shows bullish momentum.

Trade plan - actionable and time-boxed

My recommendation is a mid-term swing long with strict risk controls.

• Trade direction: Long HIMS
• Entry: $26.50
• Stop loss: $21.00 (limit close below the recent consolidation low and to keep downside manageable)
• Target: $40.00
• Horizon: Mid term (45 trading days) - expect this trade to play out over several weeks as GLP-1 prescription ramp and topline cadence become clearer and as short-covering momentum runs.

Why these levels? Entry near $26.50 buys into momentum after the news gap while leaving room for intraday slippage. The $21 stop protects against a renewed selloff that would indicate the re-rating failed; it sits beneath recent intraday swings and keeps position size disciplined. The $40 target is a realistic stretch given the company’s growth story, remaining below the prior peak yet reflecting a healthy re-rating if GLP-1 sales and guidance prove durable.

Catalysts that can push the trade higher

• Execution of the Novo Nordisk distribution partnership and public evidence of restored GLP-1 prescriptions via HIMS’ platform.
• Quarterly results or management commentary that re-accelerates revenue growth toward the $2.8B 2026 target.
• Short-covering squeeze dynamics: high short interest and recent heavy short volume can accelerate moves when sentiment shifts.
• Positive industry signals such as easing GLP-1 supply constraints or favorable pricing dynamics that improve unit economics.

Risks and counterarguments

No trade is risk-free. Here are the material downsides and the counterarguments I expect readers to raise.

• GLP-1 concentration risk. A large portion of the past surge was driven by GLP-1s. If payers, pricing pressure, or new competition erodes pricing or demand, revenue could disappoint. Counterargument: HIMS has diversified revenue streams (dermatology, sexual health, mental health) and management emphasizes non-GLP-1 contributions—so a partial GLP-1 weakness wouldn’t necessarily collapse the business.
• Valuation compression risk. The stock trades at a P/E in the mid-40s and price-to-sales around 2.3x. If investors demand higher profit visibility or growth slows, multiple contraction could erase upside. Counterargument: the market historically assigns higher multiples to platform businesses that show sustained prescription economics; re-acceleration toward the $2.8B target would justify multiple expansion.
• Execution & regulatory/legal risk. Although the Novo lawsuit was dropped, legal or regulatory headwinds around prescription promotion, telemedicine rules, or further disputes could reappear and dent confidence.
• Macro volatility and liquidity. HIMS is volatile (wide 52-week range) and sensitive to market risk-off moves. Heavy volume days and short activity can swing price violently in either direction.
• Cash flow & leverage. Free cash flow is positive but modest (~$57.4M), and debt-to-equity sits around 1.8. If growth requires additional capex or marketing spend, expect margin pressure.

Counterargument summary: Critics will argue the rooms of upside are already priced in after the rally and that GLP-1 demand/price risk remains. That is fair. This trade treats the Novo resolution as a de-risking event that materially increases the probability of hitting a re-rating; if the next quarterly cadence shows renewed top-line momentum, the reward/risk looks attractive. If it doesn’t, the stop limits losses.

Catalyst timeline and what I’ll be watching

In the coming weeks (the 45-trading-day horizon of this trade) I’ll watch three things closely: (1) early evidence of GLP-1 prescription fulfillment on HIMS’ platform, (2) any updated guidance or commentary from management about cadence toward $2.8B, and (3) short interest/short-volume trends. A sustained pick-up in orders or an operational update that quantifies GLP-1 contribution would likely push price toward the target. Conversely, a guidance cut or fresh legal/regulatory noise would invalidate the thesis.

Conclusion - stance and what changes my mind

I am constructive on HIMS as a mid-term tactical long. The Novo Nordisk partnership materially changes the probability distribution: it removes a large legal overhang while restoring access to high-value products that can scale on HIMS’ platform. Entry at $26.50 with a $21 stop and a $40 target over ~45 trading days gives a disciplined, event-driven path to profit while protecting capital if the re-rating fails to materialize.

I will change my view if any of the following happens: management issues guidance materially below the $2.8B plan; GLP-1 supply/pricing dynamics worsen materially and persist; or a new legal/regulatory event undermines prescription distribution. Until then, the Novo deal gives HIMS leverage—and this trade captures that leverage with risk controls.

Key trade details (recap)

• Entry: $26.50
• Stop: $21.00
• Target: $40.00
• Horizon: Mid term (45 trading days)
• Risk level: Medium

Note: Size this trade relative to portfolio volatility. HIMS is a high-beta, headline-sensitive name; treat it as an opportunistic, actively managed position rather than a passive core holding.